Abeona cell therapy approved by FDA for rare skin condition

Zevaskyn, which Abeona priced at $3.1 million, treats epidermolysis bullosa. It will compete with a gene therapy from Krystal Biotech that is off to a strong sales start.

Caribou, in reversal, scraps autoimmune cell therapy and cuts staff

The CRISPR company is laying off about a third of its employees and stopping work on an experimental lupus treatment in a bid to focus resources on a pair of cancer cell therapies.

The state of vaccine development in pharma

Novartis to acquire Regulus in deal for kidney disease drug

The pharma will pay $800 million for the biotech, which was launched nearly two decades ago by Alnylam and Ionis to advance microRNA technology.

Gilead leans on HIV drugs as oncology sales slow

The company is looking to the highly anticipated launch of a closely watched HIV medicine to offset weakening demand for Trodelvy and its cancer cell therapies.

Arvinas, Entrada cut staff; Merck builds US hub for Keytruda

Arvinas is laying off about a third of its workforce, while Entrada is focusing more on Duchenne research. Elsewhere, Biogen talked down tariff impacts and Merck earmarked $1 billion for a biologics production plant.

FDA’s shift from animal testing opens doors for organoid makers

First patient to receive gene therapy treatment developed at Children’s Hospital of Philadelphia living pain-free